Skip to main content

Pradaxa Lawsuit News: Pradaxa MDL Convened in District Court in Illinois for Status Conference on January 14, 2013

Pradaxa Lawsuit News: Pradaxa MDL Convened in District Court in Illinois for Status Conference on January 14, 2013Court convened in the Pradaxa Multi-District Litigation (MDL) known as In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation) MDL No. 2385 for a Status Conference on January 14, 2013. The Pradaxa MDL is being heard in the U.S. District Court for the Southern District of Illinois in East St. Louis, and is being presided over by Chief Judge David R. Herndon.

An attorney on the Plaintiffs’ Co-Lead Counsel, Roger C. Denton, delivered an update on the development of a Privilege Log, a document listing items to be withheld during legal proceedings. Both parties have come to an agreement on what items to list on the Privilege Log as well as when Boehringer Ingelheim is scheduled to begin delivering items for the Privilege Log to the plaintiffs’ counsel.

Boehringer Ingelheim’s lawyers supplied an update on defense witness depositions, which have been scheduled for March. According to the Pradaxa MDL Status Conference minutes, both parties are working on scheduling these depositions, but have come across obstacles in determining deposition locations.

To date, there are 183 cases that have been consolidated into the Pradaxa MDL in East St. Louis, Illinois.

Pradaxa is an anticoagulant drug prescribed to patients with non-valvular atrial fibrillation. As an anticoagulant medication, Pradaxa was developed by Boehringer Ingelheim Pharmaceuticals, Inc. with the expectation that the drug would be a superior alternative to warfarin, an anticoagulant drug introduced in the 1950s.

Upon authorizing approval of the drug Pradaxa in October 2010, the U.S. Food and Drug Administration (FDA) began receiving adverse event reports, and more specifically, patient reports detailing episodes of severe and uncontrollable bleeding linked to the use of Pradaxa. As a result of these serious bleeding risk reports, the FDA continues to research the health risks of ingesting Pradaxa in the prevention of strokes and blood clots in patients with atrial fibrillation.

Lawyers at Carey Danis & Lowe are currently accepting Pradaxa claims, and are working on evaluating each Pradaxa lawsuit for inclusion in the MDL in East St. Louis, Illinois. If you or someone you love has suffered a severe bleeding event while taking Pradaxa, you and your loved one may be eligible to receive recompense for such undue suffering.

To submit a Pradaxa claim and for a free legal consultation regarding your Pradaxa case, contact an experienced trial lawyer at Carey Danis & Lowe by calling 800.721.2519.